# Novartis general principles on grants to reputable healthcare (-related) organizations and patient associations.

## Application process and eligibility criteria

### General principles for all grants

Novartis may provide funding to external organizations in the interest of driving its mission to improve healthcare, advance scientific knowledge or support the communities where Novartis associates live and work. Grants can be provided to all registered medical, scientific, charitable and healthcare organizations, and patient associations.

Grants are monetary contributions provided by Novartis without intent or agreement to receive any benefit in exchange (a mere display of the Novartis logo or name is not considered a benefit; disclosing Novartis support is important from a transparency perspective, and is not considered a tangible benefit).

Grants are never provided to gain an improper advantage or prompt a favor with funding recipient.

Grants are not intended to interfere with the independent judgment of healthcare organization/ association recipients and/or their associates.

As Novartis only wishes to support actively the grant activity performed by the grant recipient, the grant is not subject to VAT.

Grants will only be given to recognized and reputable patient/healthcare organizations for the general purpose of supporting healthcare, and this in line with our commitment towards patients and caregivers. In this regard a due diligence on the organization will be undertaken. This may comprise of constitutional documentation, annual reports, web searches or evidence of previous performance or previous direct experience.

An Investigator Initiated Trial/Research or study funding request is not to be considered as a Grant. Click <u>here</u> to read more information for Investigator Initiated trials/Studies at Novartis and how to apply.

In case you would like to receive more information or in case of doubt, please reach out to your medical contact at Novartis or to our medical department (medical-1.affairs@novartis.com) before submitting your request in the Novartis GEMS platform.

Every request for support is subject to a fair review by a dedicated Novartis grant review committee, composed of appropriate Novartis experts, to ensure the acceptability, the non-promotional nature and the independence of the parties. If the outcome of the evaluation process is positive, a contract will be established.

Grant approval is objective and unrelated to any business relationship Novartis has, or may have, with grant requestors.

For transparency reasons it is requested that Novartis funding is disclosed in publications.

After issuance of the grant, you will be requested to provide to Novartis follow-up information about the effective use of the funds for the intended project.

#### **Submission requirements**

In order to be considered, a complete grant application package must be submitted to Novartis <u>prior</u> to the activity or event start date. Each request will be evaluated on its merits and the value it brings to patient care.

Annually, Novartis defines the key disease areas in which grant requests can be considered. The disease areas eligible for funding are aligned with the Novartis mission and strategic research <areas. Grants which are not within the identified key therapeutic areas of interest (see Key Areas of Therapeutic Interest) will most likely not be considered.

Grant applications must be submitted through the GEMS platform (https://www.cybergrants.com/pls/cybergrants/ao\_login.login?x\_gm\_id=2932&x\_proposal\_type\_id=51678)

#### **Grant Requests Not Supported**

- Grants which are not within the identified therapeutic areas of interest (see Areas of Therapeutic Interest)
- Grants to individuals
- Grants for activities which occurred prior to the time of the request. Such grant requests will be immediately deemed ineligible and will be declined.
- Grants to generate profit for the grant recipient; grant requests for the funding of materials or services that are invoiced to the patient do not come into consideration.
- Entertainment
- Professional career development (e.g. office/practice management skills, presentation skills, etc.)
- Request for programs that have already started or are in progress
- Activities held in lavish venues/resort locations are strongly discouraged
- Multi-year commitments

### **Key Areas of Therapeutic Interest and grant amounts**

- Multiple Sclerosis
- Dermatology: psoriasis & urticaria
- Rheumatology
- Cardiometabolic and Renal disorders
- Breast Cancer
- Malignant Haematology
- Benign Haematology
- Prostate Cancer

The Novartis grant review committee has the authority to accept or decline grant requests or ask for additional information. It has the authority to decide on the amount of the grant to be awarded and reserves the right to only partially honor grant requests. Results will be communicated after the grant review committee has made a decision. Please note that approval of funding requests may take up to three months.